Tirzepatide and CPAP preferences for obesity-OSA comorbidity surveyed among patients and providers

Obesity and obstructive sleep apnea (OSA) frequently co-occur, exacerbating health risks and cardiovascular morbidity. Continuous positive airway pressure (CPAP) is the primary OSA treatment, but adherence is often poor. While weight loss can improve OSA severity, effective pharmacological options directly targeting OSA in obese patients are limited. Tirzepatide, a dual GLP-1/GIP receptor agonist, offers significant weight reduction, making it a potential therapeutic strategy for this comorbidity. Understanding preferences for these treatments is crucial for patient-centered care and optimizing outcomes.

No specific findings or quantitative results are available in the provided correction notice. The original survey investigated patient and provider preferences for therapeutic approaches to comorbid obesity and obstructive sleep apnea, specifically comparing CPAP and tirzepatide. The correction notice itself does not detail the outcomes of these preference assessments, such as the proportion of patients preferring one treatment over another, or any statistical comparisons between groups. The core focus of the original research was to gather insights into the perceived value and acceptability of both device-based and pharmacological interventions for this complex comorbidity.